Spyre Therapeutics Inc (SYRE) Stock Analysis

Verdict: WATCH (do not buy)

A $7.7B valuation for preclinical IBD assets leaves zero margin for error if early human trials fail to beat incumbent biologics.

Investment score: 44/100

Analysis as of

Is Spyre Therapeutics Inc stock worth reviewing? The TradeMates thesis

A $7.7B valuation for preclinical IBD assets leaves zero margin for error if early human trials fail to beat incumbent biologics.

7-factor investment score

Spyre Therapeutics Inc opportunities and risks

What speaks for SYRE

What speaks against SYRE

Peers and competitors

Trailing-twelve-month ratios
TickerP/EP/SEV/EBITDAGross marginNet marginFCF yield
SYREn/a83.8xn/a0.0%-197.7%-2.8%
TGTX18.3x10.7x65.5x82.4%55.2%-0.0%
TWSTn/a17.9xn/a52.0%-31.7%-1.2%
IMVTn/a1134.8xn/a97.1%-7585.9%-5.1%
RYTMn/a29.5xn/a89.0%-85.6%-2.1%
CAI67.0x7.1x39.4x69.7%10.6%2.1%
Peer mediann/a17.9xn/a82.4%-31.7%-1.2%

Frequently asked questions about Spyre Therapeutics Inc (SYRE)

Is SYRE stock a good investment?

The TradeMates model rates Spyre Therapeutics Inc as WATCH (do not buy) with an investment score of 44/100. A $7.7B valuation for preclinical IBD assets leaves zero margin for error if early human trials fail to beat incumbent biologics. This is algorithmic model output, not personal investment advice.

Is SYRE stock a buy?

The TradeMates model verdict for SYRE is WATCH (do not buy) with an investment score of 44/100. Treat this as a model signal to review, not a personal buy recommendation.